Novel Nanoparticles for Oral Exendin-4 Delivery

Part of the IFMBE Proceedings book series (IFMBE, volume 49)


Exendin-4 is a potent insulinotropic agent in diabetes patients; however, its therapeutic utility is limited due to the frequent injections required. In this study, an orally available exendin-4 formulation, using a pH-responsive NP, was developed. Following oral administration of 123I-labeled- exendin-4 loaded NPs in rats, the biodistribution of the administered drug was investigated using a dual isotope dynamic SPECT/CT scanner. The results showed that the radioactivity of 123I-exendin-4 propagated from the esophagus, stomach, and small intestine and then was absorbed into the systemic circulation; with time progressing, 123I-exendin-4 was metabolized and excreted into the urinary bladder.


Oral delivery biodistribution exendin-4 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© IFMBE 2013

Authors and Affiliations

  1. 1.Nanomega Medical Corp.Lake ForestUnited States
  2. 2.Department of Chemical EngineeringCantho UniversityCanthoVietnam

Personalised recommendations